The mobilization of natural killer cells (uNK) triggers and coordinates all stages of embryo implantation. They are at the origin of the local secretion of cytokines, growth factors, chemokines affecting vascular development and the local immunotrophisme for the conceptus. The main objective of this study is to evaluate the expression of endometrial uNK cells before and after tubal obstruction by Essure devices. Endoluminal and endometrial levels of various cytokines and growth factors will also be studied.
Study Type
OBSERVATIONAL
Enrollment
2
Essure devices are deployed according to manufacturer's instructions for tubal sterilization.
APHP - Hôpital Antoine Beclere
Clamart, France
APHP - Centre Hospitalier Universitaire de Bicêtre
Le Kremlin-Bicêtre, France
CHRU de Montpellier - Hôpital Arnaud de Villeneuve
Montpellier, France
CHU de Nîmes - Hôpital Universitaire Carémeau
Nîmes, France
Change in number of uNK/CD56 cells per field
Number of cells per field from endometrial biopsy
Time frame: baseline (Day 0) - 3 months
% change in IL-1 beta titration in uterine flushing sample
Time frame: baseline (day 0) - 3 months
% change in IL-12 titration in uterine flushing sample
Time frame: baseline (day 0) - 3 months
% change in IL-15 titration in uterine flushing sample
Time frame: baseline (day 0) - 3 months
% change in IL-18 titration in uterine flushing sample
Time frame: baseline (day 0) - 3 months
% change in TWEAK titration in uterine flushing sample
Time frame: baseline (day 0) - 3 months
% change in TNF-alpha titration in uterine flushing sample
Time frame: baseline (day 0) - 3 months
% change in G-CSF titration in uterine flushing sample
Time frame: baseline (day 0) - 3 months
% change in G-CSF receptor titration in uterine flushing sample
Time frame: baseline (day 0) - 3 months
% change in VEGF titration in uterine flushing sample
Time frame: baseline (day 0) - 3 months
Change in the number of macrophage cells per field on endometrial biopsy
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: baseline (day 0) to 3 months
Change in the number of T cells per field on endometrial biopsy
Time frame: baseline (day 0) to 3 months
Change in expression of IL-1 beta in endometrial biopsy
Time frame: baseline (day 0) to 3 months
Change in expression of IL-12 in endometrial biopsy
Time frame: baseline (day 0) to 3 months
Change in expression of IL-15 in endometrial biopsy
Time frame: baseline (day 0) to 3 months
Change in expression of IL-18 in endometrial biopsy
Time frame: baseline (day 0) to 3 months
Change in expression of TWEAK in endometrial biopsy
Time frame: baseline (day 0) to 3 months
Change in expression of TNF-alpha in endometrial biopsy
Time frame: baseline (day 0) to 3 months
Change in expression of G-CSF in endometrial biopsy
Time frame: baseline (day 0) to 3 months
Change in expression of G-CSF receptor in endometrial biopsy
Time frame: baseline (day 0) to 3 months
Change in expression of VEGF in endometrial biopsy
Time frame: baseline (day 0) to 3 months
Change in expression of beta-2 microglobulin in endometrial biopsy
Time frame: baseline (day 0) to 3 months
Change in expression of RPL13A (reference gene) in endometrial biopsy
Time frame: baseline (day 0) to 3 months
Change in endometrial volume (cm^3)
Time frame: baseline (day 0) to 3 months
Change in subendometrial vascular flow index
Time frame: baseline (day 0) to 3 months
Time needed for Essure deployment (minutes)
Time frame: baseline (day 0), immediatly after intervention
Type of anesthesia used for Essure deployment
Time frame: baseline (day 0), immediatly after intervention
Number of spirals visible in the left uterine cavity after Essure deployment
Time frame: baseline (day 0), immediatly after intervention
Number of spirals visible in the right uterine cavity after Essure deployment
Time frame: baseline (day 0), immediatly after intervention
Presence/absence of bilateral tube obstruction
Time frame: 3 months
Change in number of uNK/CD56 cells per field
Time frame: 2 months before intervention - Day 0